What is the 13F Pro Quality Score for YCBD?

13F Pro ranks cbdMD, Inc. (YCBD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View YCBD's current score at https://13fpro.ai/research/YCBD (free sign-up required for the full ranking).

Which hedge funds own the most YCBD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of YCBD include Worth Venture Partners,, UBS Group AG, CSS /IL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/YCBD as soon as new 13F filings post.

Where does 13F Pro source YCBD data?

All cbdMD, Inc. fundamentals and ownership data come directly from SEC EDGAR. cbdMD, Inc. files with the SEC under CIK 1644903. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is YCBD in?

cbdMD, Inc. (YCBD) is classified in the Consumer Staples sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/consumer-staples.

How often is YCBD research updated on 13F Pro?

YCBD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

cbdMD, Inc.(YCBD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Consumer Staples →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1644903 YCBD stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $47.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

YCBD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for cbdMD, Inc. (YCBD), a Consumer Staples sector company. YCBD is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $47.3m in revenue. Based on the latest XBRL financial filings (Q2 2026), cbdMD, Inc. reports quarterly revenue of $5.6M, net income of $-798.0K, an operating margin of -14.2%. Top institutional holders of YCBD by reported 13-F value include Worth Venture Partners,, UBS Group AG, CSS /IL, based on the most recent SEC filings. YCBD trades on the NYSE exchange and files with the SEC under CIK 1644903. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate YCBD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for cbdMD, Inc. directly from SEC EDGAR. cbdMD, Inc.'s 13F Pro composite quality score has ranged between 10 and 32 since 2021, currently 11.6 — a declining long-term trajectory across 13 quarterly and live scoring snapshots.

Revenue

Q2 2026

$5.6M

Net Income

Q2 2026

$-798.0K

Free Cash Flow

Q2 2026

$-728.2K

Operating Margin

Q2 2026

-14.2%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-1.5% YoY

$19.2MFY 2025

FY22 $35.4MFY23 $24.2MFY24 $19.5MFY25 $19.2M

Net Income

+44.8% YoY

$-2.0MFY 2025

FY22 $-70.1MFY23 $-22.9MFY24 $-3.7MFY25 $-2.0M

Operating Income

+34.8% YoY

$-2.2MFY 2025

FY22 $-78.3MFY23 $-22.5MFY24 $-3.3MFY25 $-2.2M

EPS (Diluted)

+92.4% YoY

$-1.09FY 2025

FY22 $-55.80FY23 $-13.32FY24 $-14.29FY25 $-1.09

Total Assets

-1.5% YoY

$10.4MFY 2025

FY22 $40.8MFY23 $16.2MFY24 $10.6MFY25 $10.4M

Total Debt

—FY 2025

FY22 $125.5KFY23 $9.00FY24 —FY25 —

Op. Cash Flow

-311.7% YoY

$-1.5MFY 2025

FY22 $-15.0MFY23 $-4.3MFY24 $-352.8KFY25 $-1.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$19.2M -1.5%	$19.5M -19.3%	$24.2M -31.8%	$35.4M -20.4%	$44.5M +6.2%	$41.9M
Net Income	$-2.0M +44.8%	$-3.7M +83.9%	$-22.9M +67.3%	$-70.1M -199.6%	$-23.4M -285.6%	$12.6M
Operating Income	$-2.2M +34.8%	$-3.3M +85.3%	$-22.5M +71.3%	$-78.3M -299.0%	$-19.6M -11.6%	$-17.6M
EPS (Diluted)	$-1.09 +92.4%	$-14.29 -7.3%	$-13.32 +76.1%	$-55.80 -11772.3%	$-0.47 -267.9%	$0.28
Total Assets	$10.4M -1.5%	$10.6M -34.7%	$16.2M -60.3%	$40.8M -67.3%	$124.9M +12.7%	$110.8M
Total Debt	—	—	$9.00 -100.0%	$125.5K +15.1%	$109.0K -58.8%	$264.4K
Operating Cash Flow	$-1.5M -311.7%	$-352.8K +91.8%	$-4.3M +71.3%	$-15.0M -6.2%	$-14.1M -32.2%	$-10.7M

AI Insight: YCBD Financial Trends

Revenue stalled at $5M for nine consecutive quarters while equity deteriorated from $3M to $9M, signaling persistent operational distress.

• Revenue flatlined at $5M from Q2 2024 through Q4 2025—nine consecutive quarters with zero growth.

• Operating income and net income remained negative or break-even across all periods; Q2 2025 onward showed consistent $1M quarterly losses.

• Equity tripled from $3M (Q1 2024) to $9M (Q4 2025), driven by negative cash flow and likely dilution rather than retained earnings.

⚠ Operating cash flow remained negative throughout; Q1 2024 and Q2/Q4 2025 each burned $1M, indicating cash consumption.

⚠ Equity spike to $9M concurrent with accelerating losses suggests potential capital raise or accounting adjustments masking operational decline.

AI Insight: YCBD Ratio Trends

cbdMD swung to near-breakeven operating margin in Q4 2025 after severe losses through mid-2025, signaling potential stabilization.

• Operating margin improved from -19.6% in Q2 2025 to -5.7% in Q4 2025, recovering 13.9 percentage points in six months.

• Net profit margin similarly rebounded from -19.4% in Q2 2025 to -5.6% in Q4 2025, tracking operational gains.

• ROIC deteriorated from -50.5% in Q2 2024 to -12.7% in Q4 2025, though still negative, showing residual asset efficiency strain.

⚠ Company remains unprofitable across all metrics; Q4 2025 margin improvement may not persist without revenue growth or cost discipline.

⚠ TTM row is blank; verify whether Q1 2026 data availability will confirm sustained momentum or Q4 2025 was seasonal anomaly.

Get alerted when YCBD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for cbdMD, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of YCBD

Worth Venture Partners, LLC
$137.1K184,796 sh
UBS Group AG
$122.2K164,643 sh
CSS LLC/IL
$102.1K137,621 sh
XTX Topco Ltd
$68.3K92,049 sh
CHAPIN DAVIS, INC.
$60.3K81,250 sh
JANE STREET GROUP, LLC
$56.6K76,338 sh
ALESCO ADVISORS LLC
$50.8K68,513 sh
VANGUARD CAPITAL MANAGEMENT LLC
$37.9K51,053 sh
VANGUARD FIDUCIARY TRUST CO
$35.0K47,157 sh
Chicago Partners Investment Group LLC
$12.6K13,500 sh

Fund	Value	Shares
Worth Venture Partners, LLC	$137.1K	184,796
UBS Group AG	$122.2K	164,643
CSS LLC/IL	$102.1K	137,621
XTX Topco Ltd	$68.3K	92,049
CHAPIN DAVIS, INC.	$60.3K	81,250
JANE STREET GROUP, LLC	$56.6K	76,338
ALESCO ADVISORS LLC	$50.8K	68,513
VANGUARD CAPITAL MANAGEMENT LLC	$37.9K	51,053
VANGUARD FIDUCIARY TRUST CO	$35.0K	47,157
Chicago Partners Investment Group LLC	$12.6K	13,500

More Consumer Staples Companies

View all Consumer Staples →

ABEV

AMBEV S.A.

ABVE

Above Food Ingredients Inc.

ACI

Albertsons Companies, Inc.

ADM

Archer-Daniels-Midland Co

AFRI

Forafric Global PLC

AGCC

Agencia Comercial Spirits Ltd.

AGRO

Adecoagro S.A.

AGRZ

Agroz Inc.

Put YCBD on your watchlist

Track score changes the day cbdMD, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is YCBD a good stock to buy?

13F Pro's AI-powered analysis of cbdMD, Inc. (YCBD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Staples sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for YCBD are available on the YCBD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own YCBD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling YCBD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of cbdMD, Inc.'s investment landscape.